How to Purchase Ponatinib
Ponatinib is available at hospital pharmacies and licensed local pharmacies in countries or regions where it is approved.
Since ponatinib is not approved in mainland China, patients usually obtain it through the following formal channels:
Overseas Medical Treatment
Patients may travel to countries or regions where ponatinib is approved (such as the US and some European countries) to visit hospitals. After evaluation and prescription by a qualified local oncologist, the drug can be purchased at local pharmacies.
Authorized Medical Service Institutions
Some formal medical service institutions may provide cross-border referral and drug access consultation for eligible patients.
Clinical Trials
Patients may check for domestic clinical trials of ponatinib or similar new drugs via official channels. If enrolled, they can receive free drug treatment and professional medical monitoring.
Dosage and Administration of Ponatinib
Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (Combined with Chemotherapy)
Starting dose: 30 mg orally once daily.
Dose adjustment: After induction therapy, if minimal residual disease-negative complete remission is achieved, reduce the dose to 15 mg orally once daily.
Ph+ ALL Monotherapy (No Other TKI Applicable or T315I-Positive)
Starting dose: 45 mg orally once daily.
Chronic-Phase Chronic Myeloid Leukemia (CP-CML) (Resistant/Intolerant to At Least Two Prior TKIs)
Starting dose: 45 mg orally once daily.
Dose adjustment: When ≤1% BCR::ABL1 is achieved, reduce the dose to 15 mg orally once daily.
Accelerated-Phase or Blast-Phase CML (AP/BP-CML, No Other TKI Applicable) and T315I-Positive CML
Starting dose: 45 mg orally once daily.
Administration Instructions
May be taken with or without food. Swallow tablets whole; do not crush, split, chew, or dissolve. If a dose is missed, take the next dose at the usual time on the following day. Do not double the dose to make up for a missed one.
